A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma

Trial Profile

A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs SAR 260301 (Primary) ; Vemurafenib
  • Indications Lymphoma; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Sanofi
  • Most Recent Events

    • 04 Oct 2017 Status changed from recruiting to discontinued, according to the results published in the Cancer.
    • 04 Oct 2017 Results (n=21) assessing the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics, and efficacy of the selective PI3Kb inhibitor SAR260301 in patienstw with advanced solid tumors, published in the Cancer.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top